Market Signal Briefing

BitMine Immersion Technologies Inc. (NYSE:BMNR) shares rose 6.4% Monday after the company announced its Ethereum (CRYPTO: ETH) holdings reached 3.5 million tokens, valued at $13.2 billion in total crypto and cash assets.

BitMine Expands Ethereum Treasury to 2.9% of SupplyBitMine disclosed that it now owns 2.9% of the total ETH supply, surpassing the halfway mark toward its long-stated goal of accumulating 5%. 

The company's crypto holdings include 3,505,723 ETH valued at $3,639 per token, alongside 192 Bitcoin and $398 million in cash reserves.

Chairman Thomas "Tom" Lee said the company added over 110,000 ETH in the past week, which is a 34% increase from the prior week — after using recent market weakness to expand positions. 

"We are now more than halfway toward the ‘alchemy of 5%' goal," Lee said.

Leading Ethereum Treasury and Rising Institutional SupportBitMine remains the world's largest Ethereum treasury and second-largest overall crypto holder, behind Strategy Inc. (NASDAQ:MSTR), which holds more than 641,000 Bitcoin (CRYPTO: BTC) valued near $67 billion.

The company is backed by investors including ARK Invest's Cathie Wood, Founders Fund, Pantera, and Galaxy Digital. 

It is also one of the most actively traded U.S. equities, averaging $1.6 billion in daily trading volume — ranking 48th nationwide.

Lee emphasized Ethereum's expanding role in asset tokenization and said institutional interest is accelerating as Wall Street explores blockchain infrastructure. 

"Ethereum is a super-cycle story over the next decade," he noted.

BMNR Technical Setup Turns Constructive

BMNR Price Action (Source: TradingView)

The stock is stabilizing after a sharp pullback into the mid-$40 range. 

The daily chart shows price rebounding from support near $34–$35, which aligns with the 200-day EMA. 

If the stock maintains closes above $42, the next resistance sits at $46–$48, overlapping with the 20- and 50-day EMAs. 

A sustained breakout above that range could target the $60–$70 zone — an area that capped rallies since August. 

A close below $34 would invalidate the recovery and expose the $30 floor.

BMNR Short-Term Price Dynamics (Source: TradingView)

The lower-timeframe chart shows a clean break from a descending channel, followed by a sharp reclaim of the session VWAP. 

BMNR price is now consolidating just above VWAP, signaling that buyers are willing to hold control.

RSI on the 30-minute timeframe sits in bullish territory, reflecting momentum returning after weeks of steady selling pressure.

Read Next:

Nvidia Stock ‘Particularly Compelling,’ Could See 70% Earnings Growth In 2026, Analyst Says
Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Nov 10, 2025 at 19:15 // News

This capital raise, which totaled nearly $160 million, represents a powerful institutional affirmation of the corporate treasury strategy surrounding Bitcoin.

Strive, Inc. (Nasdaq: ASST; SATA), a publicly traded company focused on long-term Bitcoin accumulation, announced the successful closing of an oversubscribed and upsized Initial Public Offering (IPO) of its Variable Rate Series A Perpetual Preferred Stock (SATA Stock). 

Confidence despite market downturn

The most compelling aspect of the offering was the robust investor demand that forced Strive to increase the IPO size. The offering was initially targeted at 1.25 million shares but was significantly upsized to 2 million shares at $80 per share.

As reported by Investing News Network, the successful closing came immediately after a severe market correction where Bitcoin briefly dipped below the $100,000 mark for the first time in months. The high investor appetite, therefore, signals that institutional conviction in Bitcoin's long-term value proposition is unaffected by short-term price volatility.

The capital raised is specifically designed to create a Bitcoin amplification toggle. This mechanism allows the company to use non-dilutive financing (preferred equity) to significantly increase its existing Bitcoin treasury holdings (which stood at 7,525 BTC as of the announcement date). The goal is to accrete value to its common equity shareholders (ASST) by leveraging the capital to purchase more BTC.

Institutional and market significance

The successful IPO of the SATA preferred stock provides Strive with a dedicated capital pool for strategic acquisitions, positioning it to capitalize on market dips to further expand its treasury.

The upsized and oversubscribed nature of the offering confirms that traditional financial markets are providing deep, dedicated liquidity channels for companies with a clear, Bitcoin-centric corporate treasury strategy. This model, pioneered by companies like Strategy (formerly MicroStrategy), is now being refined by others to attract both equity and fixed-income investors.

The use of preferred stock to fund Bitcoin purchases offers a template for other public companies seeking exposure to the asset without diluting common equity shareholders. It provides a fixed-income-like security (the preferred stock) to conservative investors while channeling the proceeds into a growth-oriented asset (Bitcoin).

In brief
Block has launched Bitcoin payments for all of its merchants globally via its Square Bitcoin platform.
Initially launched in October, the feature will offer no fees to sellers until 2027.
Block has also launched its own Bitcoin hardware wallet and allows Bitcoin trading via Cash App.
Block, the payments infrastructure firm led by Jack Dorsey, has enabled Bitcoin payments for 4 million merchants globally using the Square Bitcoin feature of its point-of-sale platform, the firm announced on Monday.

The integration allows merchants to accept Bitcoin at checkout with instant settlement via Bitcoin’s Lightning Network, with no fees until 2027. Sellers can automatically convert a portion of their daily card sales into Bitcoin as well. 

“Square Bitcoin is the first fully integrated Bitcoin payments and wallet solution for businesses that will enable sellers to accept Bitcoin payments and automatically convert sales into Bitcoin,” Dorsey wrote in his firm’s third-quarter shareholder letter.

The firm initially introduced its Square Bitcoin platform in October and successfully demonstrated merchant acceptance at Compass Coffee, a Washington D.C.-based coffee chain shortly thereafter. 

The launch is part of the Block’s initiative to provide sellers with financial optionality and flexibility, the company said, all while bringing Bitcoin into the fold of everyday payments and commerce. 

“We’re making Bitcoin payments as seamless as card payments while giving small businesses access to financial management tools that, until now, have been exclusive to the largest corporations,” said Block’s Head of Bitcoin Product Miles Suter, in an October statement announcing the product. 

“Through Square and Cash App, we serve both sides of the counter, meaning Square is uniquely positioned to make Bitcoin everyday money, not just a store of value—while also helping sellers future-proof their operations,” he added.

As part of that push, Dorsey has been calling for a de minimis tax exemption on everyday Bitcoin transactions after a legislative effort fell short months ago. In other words, the Block CEO and X (formerly Twitter) co-founder is hoping Americans will not need to report small crypto transactions as capital gains. 

Dorsey’s firm has released other Bitcoin products as well. Last year, it launched a self-custody hardware wallet called BitKey, and its Cash App—a Venmo or PayPal rival—allows users to buy, sell, and transfer Bitcoin. A map of all global merchants that accept Bitcoin, including those using Bitcoin Square, can be found inside Cash App as well. 

Shares of Block (XYZ) are up about 0.5% on Monday, changing hands at $65.80. Bitcoin has gained about 1.7% in the last 24 hours, now trading at $105,456.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Tether, the issuer of the widely used USDT stablecoin, has announced it will spend $100 million over two years on advertising for Rumble, signalling a deepening partnership that has caused the RUM stock to soar.

The most recent XRP escrow transactions stirred up some speculation within the community.  

Some users assumed that this was Ripple's usual escrow unlock, which typically takes place during the first days of the month. 

Woah. Escrow unlock in the middle of the month?!?!

HOT Stories

— Alexander Wilkerson (@alxwilkerson) November 10, 2025 Since the term "escrow" showed up relatively late during the month, some X users were seemingly perplexed by the move. 

Ripple was not involved However, the latest transactions had nothing to do with Ripple.

As explained by XRPL sleuth @XRPwallets, which tracks notable transfers on the network, the tokens were locked and then unlocked at Flare Core Vault.  

The Flare Network is a blockchain project that integrates with XRP and other assets to enable smart contracts.

Core Vault is a key component of the FAssets system on Flare. Its purpose is to act as a liquidity hub for non‑smart‑contract assets (initially XRP) that are being brought into DeFi via Flare. 

It holds underlying assets (such as XRP) deposited by the so-called "agents" so that these assets can back the minting of FAssets (e.g., FXRP).

Notably, the Core Vault has built‑in security via time‑locked escrow accounts and daily release mechanics. The "locking" means the XRP is being transferred into the Core Vault’s smart‑contract/escrow mechanism (or underlying XRPL address) and is no longer freely tradable.

After 40 days of uncertainty, the US Government Shutdown is seemingly nearing an end. The US Senators struck a bipartisan deal to end the longest shutdown in American history.

Coinbase is launching a new platform for primary token offerings, giving retail investors in the United States access to regulated cryptocurrency initial sales for the first time since 2018.

The exchange plans to host about one token sale per month on its new platform, starting with blockchain protocol Monad, which will launch its native token for sale Nov. 17–22.

Token sales will run for one week, during which time users can submit purchase requests. After the window closes, an allocation algorithm will favor smaller buyers first, gradually filling larger orders to ensure broad participation. 

The platform will reduce future allocations for users who quickly sell their newly acquired tokens, the company said on Monday.

The platform’s algorithm is designed to facilitate fairer distribution and reduce speculative dumping, according to Coinbase. 

Source: MonadTo participate, investors must hold verified Coinbase accounts and meet the platform’s compliance requirements. Token purchases will be settled in USDC (USDC), the dollar-backed stablecoin issued by Circle. 

Projects launching through Coinbase will face a six-month lockup period, preventing founders and affiliates from selling tokens on secondary markets or over-the-counter (OTC) without Coinbase’s approval and public disclosure. 

Participation is free for buyers, while issuers pay a fee based on the amount of USDC raised, in addition to any listing costs.

The launch marks one of the first broad opportunities for US retail investors to participate in public token sales over the past few years.

The 2017–2018 ICO boomAn initial coin offering (ICO) is a fundraising method where a blockchain project sells newly created tokens directly to the public to finance its development.

The funding vehicle took off in 2017 and peaked the following year, with token sales raising $13.7 billion by the first half of 2018, more than twice the amount collected during the previous year.

Crypto offerings rapidly caught the attention of regulators. In 2017, the US Securities and Exchange Commission (SEC) suggested that certain tokens could be subject to US securities regulation if they meet the requirements for an “investment contract” under the Howey test.

In 2018, auditing firm Ernst & Young analyzed more than 140 major ICOs from the previous year and found that 86% of their tokens were trading below launch prices, while nearly a third had lost almost all their value.

The ICO boom faded after 2018 due to mounting regulatory scrutiny, widespread investor losses, and a severe bear market.

The SEC's 2017 DAO Report outlined that certain token offerings met the definition of securities under the Howey test. Source: SEC.govMagazine: Mysterious Mr Nakamoto author: Finding Satoshi would hurt Bitcoin

Can Strategy and Metaplanet survive the ETF era, where direct Bitcoin access leaves little reason to invest through corporate treasuries?

Summary

Strategy and Metaplanet face mounting pressure as Bitcoin faces heat, testing their treasury models and investor confidence.
trategy raises capital through stock offerings, convertible notes, and preferred shares, while Metaplanet combines equity sales with Bitcoin-backed debt.
Analysts warn that treasury companies like Strategy and Metaplanet trading below asset value could become takeover targets amid market weakness.
The rise of Bitcoin ETFs forces Strategy and Metaplanet to prove long-term relevance beyond being vehicles for indirect crypto exposure.

Table of Contents

Strategy and Metaplanet under pressureHow two public firms keep fueling their Bitcoin buysThe hidden fragility beneath Bitcoin treasury valuationsThe survival test of DATs 
Bitcoin’s pullback below $100,000 in early November rattled the corporate balance sheets of its largest public holders. Strategy (MSTR) and Japan’s Metaplanet (3350), two companies that built their corporate identity around Bitcoin (BTC), now face growing pressure as market sentiment weakens.

As of Nov. 10, Strategy held 641,692 BTC acquired at a total cost of $47.5 billion, averaging $74,079 per coin. Led by executive chairman Michael Saylor, the company operates more like a Bitcoin investment vehicle than a software firm. 

The latest purchase, worth $49.9 million, was made today and pushed the firm’s total Bitcoin holdings to more than $68 billion at current market value.

Metaplanet, listed on the Tokyo Stock Exchange, has undergone a complete transformation since 2024, evolving from a hospitality firm into a corporate Bitcoin treasury. It now holds 30,823 BTC valued at about $3.23 billion, making it the largest non-U.S. public company holding Bitcoin.

Despite their massive holdings, both firms’ equities have fallen sharply. Strategy’s stock trades near $239 as of Nov. 10, down 55% from its record high of $543 reached in November 2024. 

Metaplanet, after hitting a peak of 1,930 yen in June 2025, has fallen to around 427 yen, marking a steep 78% drop within months despite ongoing Bitcoin accumulation.

The downturn accelerated during Bitcoin’s correction from its October record near $126,000 to below $100,000 in early November, driven by consecutive days of net outflows from U.S. spot Bitcoin ETFs. 

Let’s dive deeper into their financial structure and how future Bitcoin price movements could alter their prospects.

How two public firms keep fueling their Bitcoin buys
Strategy and Metaplanet have built financing systems that let them continue buying Bitcoin without depending entirely on their cash reserves. Both raise funds from public markets and channel that capital into expanding their Bitcoin holdings.

Strategy uses three main methods to fund its purchases. The first is through common stock, the regular shares available for trading on the stock market. When the company issues new shares, it receives cash from investors and uses part of it to acquire Bitcoin.

The second method is through convertible notes, which are loans that allow investors to exchange their debt for company shares later, often if the stock price increases. The structure lets Strategy borrow at lower interest rates since investors anticipate potential gains if the stock performs well.

The third method involves a newer class of preferred shares called Stretch. The Series A Stretch preferred shares, traded under the ticker STRC, pay a monthly dividend that can be adjusted based on market demand. 

The goal is to maintain the share price near its stated value of $100. Company filings in October showed a 10.50% annualized rate for November.

These tools provide the firm with flexible funding options. When Bitcoin prices rise and investor sentiment improves, Strategy can issue shares or preferred stock on more favorable terms. 

When Bitcoin weakens, investors demand higher dividends or lower prices to take on added risk, which raises the company’s cost of capital. If the share price also declines, issuing new stock becomes more dilutive, reducing the ownership stake of existing shareholders.

Metaplanet follows a similar model, combining equity sales with debt financing. The management team has set a long-term target of holding 210,000 BTC by 2027. Metaplanet has also created subsidiaries in Japan and the U.S. to handle its Bitcoin-related operations.

In early November 2025, several reports indicated that Metaplanet secured a $100 million loan backed by its Bitcoin holdings. The company pledged part of its Bitcoin as collateral to obtain the loan. 

If Bitcoin’s price falls, the collateral value declines, and lenders may require additional Bitcoin or reduced borrowing. If the price rises, the company gains more flexibility to draw from its credit line.

As Bitcoin’s price slides and treasury firms trade below their net asset value, the discussion among analysts has shifted from growth to survival. 

Seb Bunney, Chief Investment Officer at Block Rewards, draws a parallel between traditional value investing and the current condition of Bitcoin-holding corporations. He refers to Benjamin Graham’s “cigar butt” strategy, where investors buy companies trading below their book value in hope of extracting one last profitable “puff.”

I have a feeling that the next significant flush in Bitcoin won’t come from retail panic or regulation; it’ll come from within the ecosystem. Bitcoin treasury companies that set out to support Bitcoin might become its biggest short-term threat.

Why: If a company holds $500…

— Seb Bunney (@sebbunney) November 7, 2025

Bunney argues that a similar pattern is unfolding in crypto, where several Bitcoin treasury companies now trade below their multiple of net asset value (mNAV). 

He defines mNAV as the ratio between a company’s market cap and the total value of its Bitcoin holdings. When the ratio drops below one, the market values the entire company at less than the worth of its Bitcoin.

According to him, “Firms trading below an mNAV of 1 are sitting ducks for a hostile takeover.” He explains that a buyer could “purchase the entire company and gain control of its Bitcoin at a 20% discount to the spot price.”

Companies like Semler Scientific (SMLR), which holds $513 million worth of Bitcoin against a $406 million market cap, represent exactly this kind of opportunity.

Bunney warns that if a deep-pocketed acquirer such as Apple or Berkshire Hathaway were to buy these discounted firms and liquidate their Bitcoin, billions of dollars worth of BTC could flood the market.

He also notes that while Bitcoin itself is antifragile, “the most liquid, censorship-resistant asset in the world can still be vulnerable in the short term to financial gamesmanship when wrapped inside fragile corporate structures.”

A parallel concern appears in the work of Omid Malekan, a professor at Columbia Business School, who believes that Digital Asset Treasuries have intensified market stress instead of absorbing it.

Any analysis of why crypto prices continue to fall needs to include DATs, because in aggregate they turned out to be a mass extraction and exit event – a reason for prices to go down.

There are a few exceptions, projects that actually tried to execute the playbook my friend and…

— Omid Malekan 🧙🏽‍♂️ (@malekanoms) November 4, 2025

Malekan describes DATs as a new class of public crypto-holding vehicles, many of which were launched “in a fashion likely to cause value destruction for crypto assets.”

He argues that DATs became “a mass extraction and exit event,” allowing insiders to cash out through complex public listings and undisclosed side deals. He adds that “raising too much money and minting too many tokens, even if they are ‘locked’ or for ‘ecosystem growth’, is the gangrene of crypto.”

“The biggest damage DATs did to aggregate crypto market cap was by providing a mass exit event for supposedly locked tokens,” he added.

Meanwhile, Pierre Rochard, host of Bitcoin for Corporations and a leading commentator on Bitcoin treasury strategies, offers a more technical view of the same issue.

If you're going to invest in bitcoin treasury companies, I think it's important to try to attribute changes in mNAV to the correct underlying factors. I think MSTR's underperformance relative to BTC YTD is because it outperformed too much in 2024 and BTC/USD upside volatility…

— Pierre Rochard (@BitcoinPierre) October 31, 2025

He examines Strategy’s recent performance and attributes its weakness to a mix of cyclical and structural factors. 

“MSTR’s underperformance relative to BTC year-to-date is because it outperformed too much in 2024,” he says, explaining that Bitcoin’s volatility has cooled since then. Rochard believes part of the current pain is a healthy correction.

He points to Strategy’s “rotation from leveraged convertible bonds to amplified perpetual preferreds,” explaining that such financing shifts can temporarily weigh on valuation yet “create the best conditions for the preferreds to grow” by improving the company’s capital structure.

The firm’s recent use of at-the-market share programs, he adds, may “put marginal pressure on mNAV” in the short term but over time “increases the company’s fundamental value by growing the collateral base.”

He views the present uncertainty as an investment opportunity, arguing that the market may be discounting Strategy too harshly.

The survival test of DATs 
Bitcoin treasury firms now face a new reality. ETFs have taken over the role once played by companies such as Strategy and Metaplanet.

Before spot ETFs became available, investors who wanted Bitcoin exposure through traditional markets often turned to these firms. Buying their stocks offered an indirect way to gain Bitcoin exposure without using exchanges or wallets.

With regulated ETFs now allowing investors to purchase Bitcoin directly, treasury firms must prove their continued relevance. Strategy’s complex funding system involving stock, notes, and preferred shares once gave it an advantage, yet that model must now show sustained value as enthusiasm fades.

Metaplanet’s position appears more fragile. Its Bitcoin-backed loan magnifies each price movement, leaving the company exposed during market downturns. Managing debt while expanding holdings will determine whether it can endure long enough to benefit from a recovery.

Smaller treasuries have even less room for error. With ETFs offering a simpler and cheaper way to access Bitcoin, many of these firms must evolve from being passive holders into credible businesses capable of generating steady cash flow.

What remains to be seen is whether these firms can evolve from vehicles of exposure into businesses with lasting purpose.

XRP/USD Daily Chart (Binance) – Source: TradingView

Congrats to those who jumped in back then, you made around 15% on your trade in just a few days.

Now, XRP is nearing a key resistance at the 200-day exponential moving average and also at the $2.65 level. These are relevant threshold that the price needs to overcome decisively (high trading volumes), to keep the rally going.

If such a breakout happens, we could witness a move to $3 in no time, especially if the government puts an end to the shutdown once and for all this week.

Swell Conference Concluded with Ecosystem Growth News
Ripple finished its widely awaited Swell Conference with a decent list of project updates.

The company that oversees the development of the XRP Ledger received a $500 million investment at a $40 billion valuation in a funding round led by Citadel Securities, a titan in the financial industry.

In addition, they revealed a recent partnership with Mastercard, WebBank, and Gemini to launch blockchain-based settlements for Ripple USD (RLUSD) to power the brand-new Gemini XRP Credit Card.

This instrument will allow users to use their RLUSD stablecoin to cover day-to-day expenditures like groceries and gas.

RLUSD recently hit a new milestone upon reaching a market cap of $1 billion, reflecting the market’s growing interest in this stable asset backed by USD liquid reserves. Right now, the token ranks 11th in the list of most valuable stablecoins. It has reached this spot in just a year.

The market also seems to be reacting positively to news that the U.S. government shutdown could soon come to an end as legislators from both sides of the aisle are finally finding some common ground.

On Thursday, the market will digest inflation data for last month. If inflation comes in below analysts’ expectations, this rally could gain further steam as it will improve the odds of a December rate cut from the Federal Reserve.

That said, market participants remain cautious as President Trump’s ongoing trade war with China could introduce new twists to the plot at any minute.320

TL;DR

The cryptocurrency HBAR surged over 10 % in the last 24 hours to around $0.1914, reflecting a strong inflow of institutional capital.
Its market capitalization stands at approximately $8.13 billion, while trading volume jumped 136 % to about $473 million.
The rally coincides with the approaching ISO 20022 compliance deadline and clear signs of growing institutional adoption.

The native token of the enterprise-focused public ledger network, Hedera Hashgraph, HBAR, has shown strong upward momentum this week, signaling that large-scale investors are driving the move rather than retail speculation. After increasing by 10.75 % in the past 24 hours and reaching a price near $0.1914, HBAR now holds a market cap of about $8.13 billion, with trading volume surging to $473 million (up 136 %), highlighting clear institutional activity. Analysts note that the combination of high liquidity and consistent network performance has attracted renewed attention from fund managers, further boosting market confidence.  

Institutional Flows And Technical Breakouts
Volume data and relative outperformance suggest HBAR is benefiting from more than short-term hype. The token’s rise has pushed HBAR ahead of broader crypto benchmarks, while volume levels 136 % above the recent average indicate fresh capital inflows rather than speculative churn. Technical indicators show HBAR breaking above key resistance levels, supporting the idea that investors are positioning for long-term growth. Networks governed by enterprise consortia, such as Hedera, whose Governing Council includes Google and IBM, add credibility to HBAR’s adoption potential.

Catalysts Align With Long-Term Growth Prospects
A key driver of HBAR’s rally is the upcoming ISO 20022 compliance deadline set by SWIFT for November 22. This favors networks capable of high-throughput, enterprise-grade distributed ledger operations. HBAR’s architecture supports high transaction throughput, low latency, and enterprise use cases, making it appealing to institutional allocations.

Rising volume and market capitalization further indicate that HBAR is moving beyond niche altcoin status into a serious contender in the crypto landscape. 

Despite bullish signals, short-term technical risks remain. Profit-taking and potential pullbacks could provide entry points for long-term holders. If institutional adoption and network usage continue to rise, HBAR may extend its growth story well beyond the current cycle. For now, the combination of increased volume, institutional interest, and enterprise-ready infrastructure positions HBAR as a digital asset with strong growth potential, attracting both traditional and crypto-focused investment strategies alike.

TL;DR

Zcash (ZEC) maintains support at $23 and resistance near $26.50.
Halo 2 drives privacy and scalability improvements without trust configuration.
Electric Coin Company (ECC) advances interoperability with Ethereum layer 2 networks.

Zcash (ZEC) is trading at approximately $24.73 USD, showing a slight upward correction following a period of market stagnation. Over the past week, ZEC has seen modest volatility, reflecting the broader uncertainty in the altcoin market, which has been influenced by Bitcoin’s consolidation around the $70,000 range.

The trading volume for ZEC remains relatively low compared to its 2021–2022 levels, suggesting a decline in speculative activity and a stronger focus from investors on long-term fundamentals and privacy-related use cases.

Zcash (ZEC) rose about 1,500% over two months and reached $750, its highest level since January 2018. Public endorsements from Naval Ravikant and Arthur Hayes helped fuel buying momentum. Hayes projects $1,000 in 2025 and a long-term target of $10,000. Market indicators now show elevated risk of a steep correction.

Recent news about the Zcash blockchain highlights ongoing development toward its Halo 2 zero-knowledge proof system, aimed at enhancing privacy and scalability without trusted setup requirements. The Electric Coin Company (ECC), which manages Zcash’s protocol development, has emphasized its commitment to improving shielded transactions and integrating cross-chain privacy solutions.

One notable update in late October 2025 involved discussions about interoperability with Ethereum Layer-2 networks, a move that could expand Zcash’s privacy utility across DeFi ecosystems. Additionally, there have been community debates surrounding the future of ZEC’s monetary policy, particularly regarding the funding mechanism for ecosystem development as the founders’ reward nears its expiration.

Market sentiment toward Zcash remains neutral to mildly bullish
Technical indicators show consolidation above the $23 support level, with resistance near $26.50. The Relative Strength Index (RSI) sits around 54, suggesting neither overbought nor oversold conditions. On-chain activity has slightly increased in the last 30 days, indicating renewed interest from privacy-focused investors. If Bitcoin maintains stability and altcoin sentiment continues to improve, ZEC could test the $28–30 range by early December. Conversely, a bearish reversal in the broader market could push the price back toward $21.

Source: CryptoQuant
CryptoQuant data highlights market overheating. The Spot Volume Bubble Map shows the largest red cluster ever for ZEC spot volume. A similar signal in 2021–2022 preceded a collapse greater than 95%. On the weekly chart, price approaches the 20-week EMA near $230, roughly 62% below current market value. The EMA often acts as a reference during corrections after rapid advances.

Propy is a blockchain-based platform designed to facilitate the buying and selling of real estate properties.

The platform utilizes blockchain technology to streamline and automate the process of property transactions, making them more efficient and secure.

Propy has its own utility token called "PRO."

Global property transactions

Propy aims to create a global real estate marketplace where users can buy and sell properties from anywhere in the world. This is particularly useful for international buyers and sellers.

It uses blockchain technology to create a secure and tamper-proof title registry. This ensures the authenticity of property titles and reduces the risk of fraud.

Moreover, smart contracts on the Propy platform facilitate and automate various aspects of the real estate transaction process, including the transfer of ownership and the release of funds. This reduces the need for intermediaries and streamlines the process.

Propy provides escrow services to securely hold funds during a transaction. Payments are released automatically when predefined conditions in the smart contract are met.

Cross-border transactions

The platform is designed to handle cross-border transactions, which can involve complex legal and regulatory requirements. Propy helps users navigate these challenges.

Users can list their properties for sale on the platform, and potential buyers can search for properties based on their preferences.

Disclaimer. This article is for informational purposes only and should not be viewed as an endorsement by Coinidol.com. The data provided is collected by the author and is not sponsored by any company or token developer. They are not a recommendation to buy or sell cryptocurrency. Readers should do their research before investing in funds.

3 mins mins

Strategy Buys 487 BTC at $102K, Holdings Now 641K BTC
 Key Insights:

Strategy’s BTC holdings rise to 641K after $49.9M buy at over $102K per coin.
Michael Saylor reports 26.1% BTC yield YTD as the firm’s average cost stands at $74K.
Traders watch $MSTR stock as the BTC price near $100K boosts investor interest again.

Strategy has confirmed a fresh purchase of 487 BTC, spending close to $49.9 million. The average price for this transaction was $102,557 per coin. This latest acquisition, shared by Michael Saylor on November 10, brings the company’s total Bitcoin holdings to 641,692 BTC. Based on public filings, these assets were acquired for roughly $47.54 billion at an average cost of $74,079 per coin.

BTC Holdings Climb as Price Surpasses Average Cost
The new purchase puts the company’s latest buy well above its average cost. The $102,557 per BTC entry is the highest reported by Strategy to date. The company has been adding to its position steadily, even during price dips earlier this year.

Michael Saylor stated that Strategy recorded a 26.1% yield on its Bitcoin holdings in 2025. This metric tracks the change in value of its BTC treasury relative to acquisition costs. “Strategy acquired 487 BTC for approximately $49.9 million,” Saylor posted, echoing the company’s official press release.

Price Action and Stock Market Response
The market often reacts to Strategy’s purchases, particularly through its stock, $MSTR. Traders use the stock as a proxy for Bitcoin exposure, with price moves in BTC regularly mirrored — and sometimes magnified — in $MSTR. When Bitcoin moves by 3%, $MSTR has shown moves up to two or three times that range.

With Bitcoin trading above $100,000 at the time of the purchase, many traders are watching $110,000 as a possible resistance level. On the downside, $100,000 is viewed as a key support zone.

Institutional Signals and Related Activity
Strategy’s public filings also mention related tickers: STRC, STRD, STRE, STRF, and STRK. These may be tied to broader digital asset initiatives. While no direct explanation was given, they suggest additional activity beyond core BTC buys.

Large purchases like this often lead to spikes in exchange volume. Traders sometimes view these events as entry signals, especially when paired with on-chain data showing accumulation. Strategy’s consistent buying continues to draw attention across both crypto and equity markets.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Rate this post

Bitcoin (CRYPTO: BTC) may face its biggest political stress test yet in 2028 when President Donald Trump leaves office and the pro-crypto administration that empowered the industry comes to an end.

Trump's Political Premium Drives Crypto ConfidenceCrypto's identity has become deeply connected to Trump's leadership. 

Polls in 2025 showed that 73% of U.S. crypto investors backed his digital asset policies, underscoring how much sentiment now hinges on his political survival. 

Trump cannot remain in office after 2028, and when his term ends, the industry loses the regulatory champion driving today's momentum.

Institutional and Retail Investors React DifferentlyInstitutional investors have built exposure under expectations of regulatory clarity.

They anticipate a cooperative SEC, bank access for custody services, and federal backing for stablecoins.

When Trump exits, those expectations vanish. 

Funds and asset managers may pause inflows until the next administration signals its approach. 

For example, after Trump's 2024 win, BlackRock (NYSE:BLK) and Fidelity's Bitcoin ETFs drew over $2 billion in inflows, but when legal uncertainty surfaced in late 2025, ETF outflows topped $180 million in a day.

Strategy Inc. (NASDAQ:MSTR), the largest public Bitcoin holder, also mirrors those cycles — its stock typically rallies on pro-crypto policy news and weakens when regulatory risk rises.

Retail investors are likely to react faster and more emotionally. 

Trump’s exit could trigger panic selling and short-term volatility as confidence fades.

Yet a segment of the base could react in the opposite way — viewing Trump's exit as proof that Bitcoin, not politics, represents true financial freedom.

Policy Direction Could Swing Back Toward EnforcementUnder Trump leadership, agencies adopted a cooperative tone toward digital assets, opening communication channels with exchanges and easing compliance pressure. 

Without him, that balance could quickly tilt back toward enforcement-led oversight.

The SEC could revert to a strict interpretation of securities laws, labeling more tokens as unregistered assets and resuming litigation against major exchanges. 

Stablecoin rules, once shaped by the GENIUS Act, might be rewritten to require issuers to operate under banking supervision. 

Trump's block on a CBDC could also be lifted, reigniting debate over a digital dollar.

In banking, regulators might reintroduce caution, discouraging lenders from offering crypto custody or services to exchanges. 

A new administration could appoint a tougher SEC chair in the mold of Gary Gensler, restoring the pre-2024 regulatory climate. 

Such a shift would likely slow institutional participation and temper the expansion of U.S.-based token projects.

Legislative Momentum Slows Without Trump's PushTrump's presence in Washington helped push through the first federal stablecoin law. 

Without him, pro-crypto legislation could lose traction, while oversight-focused proposals gain ground. 

Senator Elizabeth Warren (D-Mass.) and other skeptics could return to prominence. 

Still, Democrats aware of crypto's growing influence among young and minority voters may adjust their tone to avoid alienating an emerging voting bloc.

Bitcoin Faces Short-Term Volatility But Long-Term StrengthBitcoin's history shows how quickly political events influence price. 

It surged above $100,000 after Trump's 2024 victory and dipped around 2% in 2025 during uncertainty tied to his trade cases. 

When Trump exits in 2028, the pattern could repeat: a short-term sell-off, followed by consolidation as investors reassess regulation and macro conditions. 

Once that adjustment ends, Bitcoin's long-term drivers—halving cycles, global liquidity, and institutional adoption—should take over again.

Crypto's Post-Trump MaturityEven without Trump, Bitcoin's foundation remains independent of politics. 

His policies accelerated adoption, but the technology's core strength lies in decentralization. 

The next phase may bring less hype and more structural maturity, as markets refocus on fundamentals rather than campaign headlines.

Read Next:

Microsoft Deal Could ‘Truly Change’ How Investors See IREN, Analyst Says
Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Solana price weak rebound from $131 support tests resistance at $165–$179. Low trading volume suggests limited strength, raising the risk of a continuation in the bearish trend.

Summary

Support: $131 remains the key structural level to defend.
Resistance: $165–$179 range must be broken for trend reversal.
Volume: Weak participation limits bullish momentum.

Solana (SOL) price has experienced a modest recovery following a retest of the $131 support level, a region that previously acted as a structural pivot during prior corrections. Despite the short-term bounce, the move has been characterized by notably low trading volume, indicating a lack of bullish conviction.

The price now approaches the $165–$179 zone, which serves as the current value area low and a critical resistance range that will determine whether Solana can extend its rally or resume its downward trajectory.

Solana price key technical points

Support Rebound: Solana bounced from the $131 high-timeframe support zone.
Resistance Cluster: Price faces resistance at $165–$179, aligning with the 0.618 Fibonacci level.
Weak Volume: Low bullish participation suggests caution amid fading momentum.

SOLUSDT (1D) Chart, Source: TradingView
From a technical perspective, Solana’s structure remains fragile despite the recent rebound. The $165 region represents the value area low, while $179 corresponds with the 0.618 Fibonacci retracement, both forming a significant confluence zone of resistance. A decisive breakout above this range is required to shift short-term momentum in favor of the bulls.

Failure to reclaim $179 would indicate that this is simply another lower high in the broader bearish trend, setting the stage for a potential rotation back toward the $131 support region. The $131 zone remains a major demand area, and multiple rejections below it could drive deeper price exploration toward untapped liquidity levels beneath $120.

Current volume data further reinforces the cautionary tone. The rally from $131 has not been supported by meaningful bullish influxes, making it vulnerable to a sharp reversal if market sentiment weakens. Without sustained buying pressure, this rebound risks being classified as a corrective relief rather than a trend reversal.

Broader market conditions remain uncertain, with Bitcoin consolidating near key levels and overall altcoin momentum appearing weak. Solana’s inability to attract strong participation at this stage highlights that the market remains cautious and risk-off, especially following recent corrections across major cryptocurrencies.

What to expect in the coming price action
As long as Solana holds above $131, short-term bounces remain possible, but confirmation of an actual reversal requires a clean break above $179. A failure to do so will likely result in renewed selling pressure and a return to range-bound trading.

Venture Global, Inc. (VG) Q3 2025 Earnings Call November 10, 2025 9:00 AM EST

Company Participants

Benjamin Nolan - Senior Vice President of Investor Relations of Venture Global LNG
Michael Sabel - Founder, Executive Co-Chairman of the Board & CEO
Jonathan Thayer - Chief Financial Officer

Conference Call Participants

John Mackay - Goldman Sachs Group, Inc., Research Division
Vrathan Reddy - JPMorgan Chase & Co, Research Division
Manav Gupta - UBS Investment Bank, Research Division
Jean Ann Salisbury - BofA Securities, Research Division
Christopher Robertson - Deutsche Bank AG, Research Division
Bob Brackett - Sanford C. Bernstein & Co., LLC., Research Division

Presentation

Operator

Good morning, and welcome to the Venture Global Inc. Third Quarter 2025 Earnings Conference Call.

At this time, I would like to turn the conference call over to Ben Nolan, Senior Vice President, Investor Relations. Please go ahead.

Benjamin Nolan
Senior Vice President of Investor Relations of Venture Global LNG

Thank you, Joanna. Good morning, everyone, and welcome to Venture Global Inc.'s Third Quarter 2025 Earnings Call. I'm joined this morning by Mike Sabel, Venture Global's CEO, Executive Co-Chairman and Founder; Jack Thayer, our CFO; and other members of Venture Global management team.

Before I begin, I would like to remind all listeners that our remarks, including answers to your questions, may contain forward-looking statements, and actual results could differ materially from what is described in these statements. I encourage you to refer to the disclaimers in our earnings presentation, which is available on the Investors section of our website. Additionally, we may include references to certain non-GAAP metrics such as consolidated adjusted EBITDA. A reconciliation of these metrics to the most relevant GAAP measures can be found in the appendix of the earnings presentation posted on our website.

Finally, the guidance in this presentation is only effective as of today. In general, we

Recommended For You

Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed

Sydney Mass Spectrometry is the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, adding to a growing list of institutions revealing biological insights with exceptional clarity at scale

Recent collaborations and projects including Genomics England and PRECISE-SG100K highlight advancements in proteomic profiling across diverse populations and research areas

, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Protein Prep is delivering the broadest coverage of the blood proteome on the market at the lowest cost per protein target for more than 40 customers across 16 sites globally. Labs of all sizes are creating powerful layers of omic data for a range of diseases that enrich datasets generated by biobank programs around the world.

"We believe in the power of proteomics to give research and clinical labs—big and small—the deepest look into the biology underwriting human health," said Steve Barnard, PhD, chief technology officer of Illumina. "Our customers are harnessing the potential to enrich genomic studies at scale with exceptional specificity, sensitivity, and precision, transforming real-world insights into impactful discoveries."

Illumina Protein Prep empowers researchers to seamlessly integrate comprehensive proteomics into large-scale genomics studies, dramatically accelerating breakthroughs across cancer and cardiometabolic and immunologic diseases. Illumina is providing the AI-driven infrastructure to fully realize this vision with DRAGEN and Illumina Connected Multiomics, delivering both secondary and tertiary analysis in one workflow.

Depending on the use case, the Illumina Protein Prep solution offers an accessible alternative or complement to mass spectrometry, allowing researchers to derive transformative insights, increasing their discovery power.

Sydney Mass Spectrometry adopts Illumina Protein Prep to expand proteomic offerings

As the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, Sydney Mass Spectrometry recently completed their first real-world experiment using blood plasma samples from a clinical trial to study dietary interventions in subjects with metabolic disease. Illumina Protein Prep identified significant differences between cohorts on a grouped basis, leading researchers on a path to further validate several novel candidates.

"We believe Illumina Protein Prep is a powerful proteomics solution to fuel large-scale strategies for various proteome- and genome-matched projects for translational research," said Professor Stuart Cordwell, PhD, academic director of Sydney Mass Spectrometry, The University of Sydney. "As a lab that has historically focused on mass spectrometry, we see a robust opportunity for these technologies to serve as alternatives or complements due to Illumina Protein Prep's broad, dynamic range and large discovery panel of over 9500 proteins."

The proteomic insights were all generated using Illumina platforms and software. Next, the facility intends to benchmark existing large clinical mass spectrometry studies with Illumina Protein Prep.

Genomics England expanded study advances rare disease research

As an early-access customer, Genomics England used Illumina Protein Prep as part of a larger multiomics initiative for its 100,000 Genomes Project. Initial data revealed last month at the annual ASHG conference in Boston demonstrated a 7.5% increase in disease classification when genomics and proteomics were integrated in previously undiagnosed patients. The expanded study aims to validate the initial findings and discoveries of abundant differential proteins in specific disease categories.

"Our experience with Illumina Protein Prep continues to validate my confidence in the potential of proteomics to revolutionize our understanding of both rare and common disease," said Professor Matthew Brown, chief scientific officer of Genomics England. "Data from this study and others like it will create a ripple effect for large-scale studies around the world—every new layer of omic insights increases the quality and depth of the pathways we can uncover, from genetic variants to protein expression to drug discovery." 

Proteomics is key to decoding disease across diverse datasets

Biobanks are increasingly focused on understanding molecular mechanisms of disease in historically underrepresented populations. Now, proteomics is creating the vital bridge between population-specific genetic variants and their affected proteins.

Singapore's PRECISE-SG100K study is using Illumina Protein Prep to run 10,000 plasma samples to expand upon its previous proteomic profiling project, with a goal to develop a standardized dataset that can be used to interrogate potential therapeutic targets.

"We established this program with the intent to reach a deeper understanding of how diseases develop and discover better treatments in Asian populations," said Professor John Chambers, PhD, chief scientific officer of PRECISE and lead PI of SG100K. "Building on our collaboration with Illumina, we are looking forward to making our dataset even more impactful for researchers seeking representative multiomic markers for precision medicine."

Additional proteomics news from Illumina

Illumina showcased Illumina Protein Prep and Illumina Connected Multiomics this week at the Human Proteome Organization World Congress. Presentations will be available to view on demand here after the conference. For more on Illumina's multiomics solutions, follow this link.

In June, Illumina announced a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic. Until the transaction closes, which is subject to customary closing conditions, including the receipt of required regulatory clearance, Illumina and SomaLogic will continue to operate as separate and independent entities.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations; and (iv) our ability to obtain any required regulatory clearances to close our acquisition of SomaLogic, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
 Illumina Investor Relations
 858-291-6421
 [email protected]

Media:
 Christine Douglass
 [email protected]

SOURCE Illumina, Inc.

Gold's recent correction isn't the start of a bear market for the yellow metal. Bulls point to more upside ahead.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of IWM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The author is not an investment advisor and offers no advice here. He shares his own analysis solely for the interest of readers.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Lantheus Holdings, Inc., (“Lantheus” or the "Company") (NASDAQ: LNTH) investors of a class action on behalf of investors that bought securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”). Lantheus investors have until November 10, 2025 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or join the case via https://portnoylaw.com/lantheus-holdings-inc/. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The complaint alleges that Lantheus and its executives misled investors about the growth and pricing strength of Pylarify, its key prostate cancer imaging product, during the class period. The company repeatedly assured investors that Pylarify’s market leadership and premium pricing would support revenue growth, while concealing that price hikes and competitive pressures were eroding its market position. When quarterly results in May and August 2025 revealed sharp sales declines, reduced guidance, and intensifying competition, Lantheus’ stock dropped over 23% and 28% on those respective dates. The lawsuit claims that investors purchased shares at artificially inflated prices due to these misrepresentations.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

Government Shutdown Possibly Coming to an End.

Merck & Co., Inc. (MRK) Shareholder/Analyst Call November 9, 2025 7:01 PM EST

Company Participants

Peter Dannenbaum - Vice President of Investor Relations
Dean Li - Executive VP & President of Merck Research Laboratories
Joerg Koglin - Senior VP & Head of General Medicine - Global Clinical Development
Jannie Oosthuizen - Senior VP & President Merck U.S. Human Health

Conference Call Participants

Taylor Hanley - JPMorgan Chase & Co, Research Division
Daina Graybosch - Leerink Partners LLC, Research Division
Nick Jennings - Goldman Sachs Group, Inc., Research Division
Malcolm Hoffman - BMO Capital Markets Equity Research
Vamil Divan - Guggenheim Securities, LLC, Research Division
Courtney Breen - Sanford C. Bernstein & Co., LLC., Research Division
Steve Scala - TD Cowen, Research Division

Presentation

Operator

Welcome to the Merck & Co., Inc., Rahway, New Jersey, U.S.A. AHA Investor Event. [Operator Instructions] This call is being recorded. If you have any objections, you may disconnect at this time.

I would now like to turn the call over to Mr. Peter Dannenbaum from Senior Vice President, Investor Relations. Sir, you may begin.

Peter Dannenbaum
Vice President of Investor Relations

Thank you, Ivy. Good evening, and welcome to Merck's investor event coinciding with the American Heart Association Scientific Sessions 2025. Thank you to those with us here in New Orleans and also to those participating via the webcast. We appreciate your interest in Merck.

Before we get started, I'd like to remind you that some of the statements that we make today may be considered forward-looking statements within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are made based on the current beliefs of our company's management and are subject to significant risks and uncertainties. If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the

Recommended For You

In-the-know traders see Taiwan Semiconductor Manufacturing (NYSE:TSM) as global powerhouse among chipmakers.

Key Takeaways The Medical sector shows strong Q3 trends, with most firms beating earnings and revenue estimates.Four biotech firms, Alto, Autolus, Ascendis, and Immuneering, match criteria for likely earnings beats.Each holds positive Earnings ESP and solid ranks, boosting odds of outperforming when results are released.
The third-quarter 2025 reporting cycle of the Medical sector is currently approaching its end. The sector primarily comprises pharma/biotech and medical device companies.

Many pharma giants, like Amgen, Novo Nordisk and Pfizer, reported earnings last week. While results for Amgen and Pfizer were strong on both earnings and sales, both companies also raised their EPS outlook for 2025. However, things did not look good for Novo Nordisk, which reported weaker-than-expected Q3 results. The Danish drugmaker also slashed its guidance outlook for the full year due to the slower growth of its GLP-1 portfolio amid increased availability of compounded alternatives and intensifying competition from arch-rival Eli Lilly.

The Earnings Trends report indicates that as of Nov. 5, nearly 82% of the companies in the Medical sector — representing 92% of the sector’s market capitalization — reported quarterly earnings. While about 92% of participants beat on earnings, around 84% outperformed revenues. Earnings rose over 4% year over year, while revenues increased nearly 11%. Overall, third-quarter earnings and sales are expected to rise 3.0% and 10.5%, respectively, from the year-ago quarter’s reported figures.

Zeroing in on WinnersWhile most companies in the sector have reported earnings, there are some companies which are yet to report. Out of them, we have highlighted four biotech companies — Alto Neuroscience (ANRO - Free Report) , Autolus Therapeutics (AUTL - Free Report) , Ascendis Pharma (ASND - Free Report) and Immuneering (IMRX - Free Report) — that seem poised to deliver a beat in their upcoming quarterly results.

Earnings ESP is our proprietary methodology for determining the stocks with the best chance to deliver an earnings surprise. It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.

According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.

Our research shows that the chance of an earnings surprise for stocks with this combination is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

4 Biotech Stocks That Match the CriteriaAlto NeuroscienceAlto is a clinical-stage biotech focused on developing a broad range of novel pipeline therapies targeting neuroscience indications like bipolar depression, major depressive disorder and schizophrenia. The company has an Earnings ESP of +16.41% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for the third quarter is pegged at a loss of 66 cents per share.

ANRO beat on earnings in three of the trailing four quarters and missed the mark once, delivering an average surprise of 4.36%.

Autolus TherapeuticsA commercial-stage company, Autolus is primarily focused on developing, manufacturing and marketing next-generation T cell therapies targeting cancer and autoimmune diseases. The company has an Earnings ESP of +22.30% and a Zacks Rank #2 at present. The Zacks Consensus Estimate for third-quarter bottom line is pegged at a loss of 23 cents per share.

AUTL beat on earnings in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 6.55%. The company is scheduled to release results on Nov. 12, before the opening bell.

Ascendis PharmaThe company is a commercial-stage biotech focused on developing and marketing therapies targeting growth disorders and rare endocrine diseases. Ascendis has an Earnings ESP of +34.28% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for third-quarter bottom line is pegged at a loss of 41 cents per share.

ASND beat on earnings in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 11.15%. It is scheduled to report earnings on Nov. 12, after the market closes.

ImmuneeringThe company is a clinical-stage biotech focused on developing its lead pipeline candidate targeting tumors harboring the RAS mutation. It has an Earnings ESP of +21.62% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for third-quarter earnings is pegged at a loss of 37 cents per share.

IMRX beat on earnings in one of the trailing four quarters, met the mark once, but missed the mark on the other two occasions. It delivered a negative average surprise of 7.82%. The company is scheduled to report earnings on Nov. 12, after the market closes.

Citi has raised its price target on Nvidia (NASDAQ: NVDA) to $220 from $210 while maintaining a ‘Buy' rating, as analyst Atif Malik anticipates strong third-quarter results and higher guidance supported by surging AI-related demand.